Join
Live feed
·
PRReleasevia Quantisnow
Evommune Inc. logo

Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis

ByQuantisnow·Wall Street's wire, on your screen.
EVMN· Evommune Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track EVMN (Evommune Inc.) and more on Quantisnow.